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Abstract
Background: Serotonin (5-HT) mediates pain by peripheral 5-HT3-receptors. Results from a few studies indicate
that intramuscular injections of 5-HT3-antagonists may reduce musculoskeletal pain. The aim of this study was to
investigate if repeated intramuscular tender-point injections of the 5-HT3-antagonist granisetron alleviate pain in
patients with myofascial temporomandibular disorders (M-TMD).
Methods: This prospective, randomized, controlled, double blind, parallel-arm trial (RCT) was carried out during at
two centers in Stockholm, Sweden. The randomization was performed by a researcher who did not participate in
data collection with an internet-based application (www.randomization.com). 40 patients with a diagnose of M-TMD
according to the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) were randomized to receive
repeated injections, one week apart, with either granisetron (GRA; 3 mg) or isotonic saline as control (CTR).
Results: The median weekly pain intensities decreased significantly at all follow-ups (1-, 2-, 6-months) in the GRA-group
(Friedman test; P < 0.05), but not in the CTR-group (Friedman-test; P > 0.075). The numbers needed to treat (NNT) were 4
at the 1- and 6-month follow-ups, and 3.3 at the 2-month follow-up in favor of granisetron.
Conclusions: Repeated intramuscular tender-point injections with granisetron provide a new pharmacological treatment
possibility for myofascial pain patients with repeated intramuscular tender-point injections with the serotonin type 3
antagonist granisetron. It showed a clinically relevant pain reducing effect in the temporomandibular region, both in a
short- and long-term aspect.
Trial registration: European Clinical Trials Database 2005-006042-41 as well as at Clinical Trials NCT02230371.
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Background
Musculoskeletal pain is the most common cause of re-
duced work capacity and sick leave, and as result a sig-
nificant health problem. Already in 2003, the annual
yearly costs in Europe were estimated to be 34 billion
Euro [1]. The impact of musculoskeletal pain is not only
the unpleasant sensory experience but also an emotional
experience with feelings of failure, misery, guilt, alienation,
and co-morbid depression [2, 3]. Temporomandibular dis-
orders (TMD) is a collective term embracing chronic pain
conditions affecting the temporomandibular joint (TMJ)
or the masticatory muscles (myofascial TMD; M-TMD)
and their associated structures [4]. TMD has a prevalence
of approximately 10–20 % and is 1.5 to 2 times more
prevalent in women [5–7]. It is often associated with
restricted mouth opening capacity, pain upon chewing,
muscle soreness and headache, thus affecting quality of
life considerably although it is not life threatening.
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The neurotransmitter serotonin (5-hydroxytryptamine;
5-HT) is an important component of the chemical milieu
during inflammation [8]. It is found in high concentrations
in platelets, enterochromaffin cells, and in certain regions
of the brain [9]. Peripherally, it is released from platelets
and mast cells due to tissue damage or ischemia. 5-HTcon-
centrations have been found to be significantly elevated in
painful muscles of patients with chronic myalgia [10–12].
Evidence suggests that 5-HT activates the 5-HT3-receptor
to mediate muscle pain and mechanical sensitivity [13–15].
In a recent study it was shown that the 5-HT3A-receptor is
highly expressed in human masseter muscles and that more
nerve fibers express 5-HT3A-receptors in women with
M-TMD compared to healthy women [16]. Therefore,
targeting peripheral 5-HT3-receptors with drugs that
block these receptors could be an interesting therapeutic
approach for chronic muscle pain.
Indeed, several specific 5-HT3-antagonists have been
tested experimentally and clinically for treatment of muscle
pain. Experimentally, systemic administration of grani-
setron increased the pressure pain threshold (PPT) over
healthy muscles [17], while local administration reduced ex-
perimental pain and allodynia [14, 18]. Systemic adminis-
tration of tropisetron had a positive analgetic effect in
fibromyalgia [19, 20], whereas ondansetron reduced post-
operative pain and enhanced the postoperative analgesic ef-
fect of paracetamol [21]. However, systemic administration
of 5-HT3-antagonists is often associated with bothersome
constipation which may affect treatment compliance. For
localized pain conditions local administration has therefore
been used with positive results [22, 23]. Even if these stud-
ies were not placebo-controlled, the combined results indi-
cate that 5-HT3-antagonists may be effective to use as a
new, additional therapeutic approach for both acute and
chronic muscle pain. In our knowledge, no randomized
controlled study (RCT) has yet investigated the long-term
effect of local administration of 5-HT3-antagonists in
chronic pain-conditions.
Consequently, this study was designed to investigate if
local treatment with repeated intramuscular tender-point
injections of granisetron could be effective in alleviating
pain in patients with chronic M-TMD. The hypothesis
was that local treatment with granisetron would be super-
ior to isotonic saline (control-substance) regarding the
outcome domains recommended for pain trials by the Ini-
tiative on Methods, Measurement, and Pain Assessment
in Clinical Trials (IMMPACT) [24, 25].
Methods
Patients
Based on the information given on 1753 referrals for
TMD, 437 patients with a main complaint M-TMD pain
were subjected to a screening by the principal investiga-
tor (N.C.) who enrolled the patients. Forty patients (37
women and 3 men) were found eligible and included in
this study; none declined participation (Fig. 1). Accord-
ing to the power calculation based on a previous study
[26], inclusion of 17 patients in each group would be
sufficient to detect a statistically significant difference of
30 % (SD 30 %), between interventions at a significance
level of 5 % with a power of 80 %. In order to compen-
sate for dropouts three additional patients were included
in each group.
The inclusion criteria for the patients were; 1) age ≥
18 years, 2) a diagnosis of myofascial pain according to the
Research Diagnostic Criteria for TMD Axis I (RDC/TMD)
[27], 3) duration of TMD-pain ≥3 months, 4) self-assessed
average M-TMD pain intensity of ≥ 30 mm on a 100-mm
visual analogue scale (VAS) during one week prior to
examination, and 5) pain upon digital palpation of the
masseter and/or the temporalis muscles. The patients
remained included with one or several co-diagnoses of; a)
disc displacement with or without reduction [27], b)
osteoarthrosis [27] in the any of the TMJs, and c) tension
type headache [28].
The exclusion criteria for the patients were; 1) diagnosed
systemic muscular or joint diseases (e.g. fibromyalgia,
rheumatoid arthritis, ankylosing spondylitis, psoriatic arth-
ritis), 2) whiplash associated disorder, 3) neuropathic pain
or neurological disorders (e.g. myasthenia gravis, orofacial
dystonia), 4) history of psychiatric disorders, 5) pain of
dental origin, 6) use of muscle relaxants or any medication
that might influence the response to pain, 7) pregnancy or
lactation, and 8) known hypersensitivity to granisetron.
The study was approved by the regional ethical review
board in Stockholm, Sweden (2006/192-31/4) and by
the Medical Products Agency in Uppsala, Sweden
(151:2006/7947), registered in the European Clinical
Trials Database (2005-006042-41) as well as at Clinical-
Trials.gov (NCT02230371). The study was carried out in
compliance with the Declaration of Helsinki as well as the
International Conference on Harmonisation Guideline for
Good Clinical Practice. All participants received both writ-
ten and verbal information prior to inclusion and gave
their verbal and written consent.
Study protocol
This prospective, randomized, controlled, double blind,
parallel-arm trial (RCT) follows the consolidated standards
of reporting trials (CONSORT) statement [29, 30] and was
carried out during the period of May 2006 to December
2014 at two centers, the specialist clinics for Orofacial
Pain and Jaw Function, Department of Dental Medicine,
Karolinska Institutet, Huddinge, Sweden and Clinical Oral
Physiology at the Eastman Institute, Stockholm Public Den-
tal Health (Folktandvården Stockholms län AB), Stockholm,
Sweden.
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The patients were divided randomly into two groups
that received either granisetron or control substance. The
randomization was performed by a researcher (ME) who
did not participate in data collection with an internet-based
application (www.randomization.com). The program gener-
ated a numbered list with the substances in random order
in blocks of four. The list was kept hidden to the examiners
during the entire study and the block size as well as sub-
stances not revealed until the last patient had undergone
the last follow-up. The study substances have identical
appearance, smell and viscosity so both the patients
and examiners were blinded to group assignment. A re-
search assistant assigned the patients to treatment sub-
stance in consecutive order according to the randomization
list, prepared the syringes and marked them with patient
number. Three orofacial pain specialists (NC, LF, BHM)
and two DDS undergoing specialist training in orofacial
pain (SO, SL), who were repeatedly calibrated to a gold
standard examiner (ME) in the RDC/TMD examination
during one day, performed the study.
The study comprised seven visits; V1) Screening for
study participation and inclusion, V2-V4), Injection of
Fig. 1 CONSORT flowchart. Flowchart of the 40 participating patients throughout the study. The patients were referred for treatment of
myofascial temporomandibular disorders
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study substances, and V5) Follow-ups at 1-month. Those
patients in any group that still reported more than 30 %
improvement at the 1-month visit follow-up were sched-




Granisetron (KYTRIL®; 1 mg/mL, Roche, Stockholm,
Sweden) was used as active treatment (GRA-group) and
isotonic saline (NaCl; 0.9 mg/mL, Fresenius Kabi, Uppsala,
Sweden) was used as control treatment (CTR-group).
Granisetron is used to treat chemotherapy-induced and
postoperative nausea and vomiting and is among the
drugs that exhibit the most selective binding to the 5-
HT3-receptor, with an affinity to the 5-HT3-receptor that
is up to 40,000-fold of any other receptor. Granisetron is
not dependent on the isoenzyme cytochrome P450 2D6
(CYP2D6), possibly leading to a good efficacy also in ultra-
rapid metabolizers and has, unlike the other 5-HT3-recep-
tor antagonists, a long half-life [31–33]. It is considered
efficacious and safe with only few, passing side-effects.
The chosen solution was slowly injected into a maximum
of six muscle sites in each patient. The most painful
tender-points to palpation of the masticatory muscles
were chosen, maximum 3 per muscle. The injected vol-
ume into each tender-point was 0.5 mL. Thus the max-
imum dose of granisetron a patient could receive was
3 mg per treatment. The dose is equivalent to the dose of
the 5-HT3-receptor antagonist tropisetron used for trigger
point injections in similar studies [23, 26, 34].
The injections were made perpendicular to the skin
surface over the chosen tender-point with an angle of
90° using a 19-mm long needle (diameter 0.4 mm) from
a 2-mL syringe. The solution was administered into each
tender-point as a single shot during 10 s. In order to en-
sure intramuscular administration, during the study, the
injections were guided by electromyography (Allergan
AB, Stockholm, Sweden) in order to ensure intramuscular
administration. The injections were repeated after 1- and
2-weeks in the most painful tender-points at that time.
Follow-ups
Follow-ups were performed by questionnaires, pain as-
sessment, clinical examination and recordings of PPT.
Patients who did not respond to treatment were offered
additional treatment at the 1-month follow-up and were
excluded from further analyses. They were thus regarded
as non-responders in the intention-to-treat-analyses
(ITT-analyses), Fig. 1.
Treatment outcome measures
The IMMPACT recommends six core domains to be re-
ported in RCTs; participant disposition, pain intensity,
physical functioning, emotional functioning, participant
ratings of overall improvement and adverse events [24,
25]. The change in weekly pain intensity from baseline
was the primary outcome measure. The other domains
recommended by IMMPACT served as secondary out-
come measures.
Additional outcome measures were changes in PPT,
5-HT platelet poor plasma (P-5-HT), as well as pain
distribution.
Pain characteristics
Pain intensity was retrieved from the 1-week pain diary.
This was composed of seven 0–100 mm visual analogue
scales (VAS) with the endpoints marked “no pain” (0)
and “worst experienced pain” (100) for daily assessments
of the average orofacial pain intensity the week preced-
ing each visit. For each patient the average pain intensity
during that week was calculated (called weekly pain in-
tensity). Several repeated assessments are shown to be a
more valid measure of pain intensity than a single as-
sessment [35]. The present study reports both 30 % and
50 % pain reduction, since ≥30 % and ≥50 % reductions
of chronic pain respectively reflect a clinically relevant
pain reduction and substantial improvement [36]. The
patients further marked their pain distribution on two
lateral views of the head, one for each side separately.
Physical functioning
Physical functioning was classified using the Graded
Chronic Pain Scale (GCPS) [37] and the Jaw Disability
Checklist (JDC), both included in the RDC/TMD Axis II
questionnaire [27]. The GCPS severity scale is divided
into two parts. The first part is used to assess character-
istic pain intensity and the second part limitations in
physical functioning due to pain. When assessing phys-
ical functioning a disability score (DP 0–6) is combined
with pain intensity (0–100) as follows: Grade 0 = no
TMD-pain in the previous 6 months; Grade I = low dis-
ability (<3 DP) and low intensity pain (<50); Grade II =
low disability (<3 DP) and high intensity pain (>50);
Grade III = high disability, moderately limiting (3–4 DP
regardless of pain intensity); Grade IV = high disability,
severely limiting (5–6 DP regardless of pain intensity).
JDC was used for assessment of limitation in jaw
function. The JDC consists of twelve questions asses-
sing to which extent TMD interferes with activities
specifically related to the mandibular function. It has a
maximum of 12 points where 0 = no limitation in any
mandibular function and 12 = limitations in all mandibular
functions.
In addition, the pain-free mouth opening and the
maximum voluntary mouth opening (MVO), including
the vertical overbite, was assessed in millimeters with
a ruler.
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Emotional functioning
The changes in emotional functioning were assessed
using the modified SCL-90-R instrument in the RDC/
TMD Axis II questionnaire [27]. This includes twenty
questions indicating depression and 12 questions indi-
cating nonspecific physical symptoms (NSPhS). The total
score is calculated (graded: 0–4). The degree of depression
was classified as normal (<0.535), moderate (0.535-1.105)
or severe (>1.105), while the classification for NSPhS is:
normal (<0.5), moderate (0.5-1) and severe (>1).
Overall improvement
The patients overall improvement was assessed on a
6-point rating scale: 0 = symptom-free; 1 = much better;
2 = better; 3 = unchanged; 4 = worse; 5 = much worse.
This scale is commonly used and validated [36, 38].
Adverse events
In order to estimate any adverse events the patients were
asked to list any adverse event during the week following
each injection. If any adverse event occurred they were
asked to describe the event and to grad it as mild, mod-
erate or severe.
Assessment of pressure pain threshold
To assess the PPT an electronic pressure algometer
(Somedic Sales AB, Hörby, Sweden) was used. This de-
vice consists of a grip with a pressure-sensitive strain
gauge at the tip and a display unit. The 1 cm2 probe tip
was covered with a 1 mm thick rubber pad to minimize
the risk of irritation of the skin. The algometer was held
perpendicular to the skin surface over the muscles and
the pressure was increased at a standardized rate of 50
kPa per s. The patients were instructed to press a signal
button when the sensation of “pressure” changed into
“pain”. This was first performed over the soft tissue close
to the base of the thumb on the dorsal side of the right
hand, in order to accustom the subject to the procedure.
Recordings of PPT were made bilaterally over the most
prominent points of the masseter muscles as well as over
a reference point on the tip of the right index finger. An
extra-cranial reference point was chosen to investigate any
possible systemic effects by the study treatments. When
assessing the PPT the mean value of 3 measurements with
an interval of 2 min was used.
Blood sampling
A blood sample (5 mL) was collected from the decubital
vein in EDTA-containing tubes for P-5-HT. The sample
was immediately cooled and centrifuged (1700 G) for
30 min. Approximately 200 μL of the supernatant was
then collected with a pipette into polystyrene tubes and
kept frozen at −80° until the analysis. The plasma sam-
ples were analyzed in our laboratory with a commercial
EIA-Serotonin kit (No IM1749, Immunotech, Beckman
Coulter, Marseille, France). The kit has a sensitivity of
0.5 nM, and according to the manufacturer it has an
intra-assay coefficient of variation between 8.9 % and
14.5 %, and an inter-assay coefficient variation between
9.9 % and 11.5 %.
The patients were asked to avoid tryptophan-rich food
(e.g. eggs, milk, chicken, turkey, tomato, banana, pine-
apple, and chocolate) for 24 h before the examination to
exclude any risk of interference with the analysis of 5-HT.
Statistical analyses
The statistical analyses were performed using SigmaPlot
software version 13.0 (Systat software Inc., San Jose, CA,
USA). Normality of the data was tested with the Shapiro-
Wilk test. Descriptive data are reported as frequencies,
means and standard deviation (SD) or median and inter-
quartile range (IQR). For analyses of group differences in
frequencies χ2-test was used. For analyses of group differ-
ences of variables on a nominal scale t-test was used, while
the Mann–Whitney U-test was used for variables on an or-
dinal scale. The Friedman’s analysis of variance (ANOVA)
on ranks with Dunn’s test as post hoc test was used for
analyses of changes between baseline data and follow-up
measurements regarding pain variables and emotional
functioning, while 2-way repeated measures ANOVA with
Holm-Sidak as post hoc test was used for physical func-
tioning and changes in PPT. The Pearson correlation-test
with Bonferroni-correction for multiple comparisons was
used to correlate the P-5-HT levels with baseline and out-
come variables. The significance level was set at P < 0.05.
Results
The results are presented for both patient centers
combined (Karolinska Institutet, Huddinge, Sweden
and Eastman Institute, Stockholm Public Dental Health
(Folktandvården Stockholms län AB), Stockholm, Sweden)
since there were no significant differences for any of the
study outcomes between them.
There were no differences between the active treat-
ment group (GRA-group) or the control group (CTR-
group) regarding demographic data (Table 1).
Further, there were no significant differences between
the groups regarding baseline pain variables or self-
reported clenching/grinding (Table 2). All patients re-
ported moderate to severe tenderness to palpation of
the masseter and/or temporalis muscles. The patients’
distribution of diagnoses according to RDC/TMD Axis
I are presented in Table 2. All patients had a diagnosis
of myofascial pain. Most patients (87 %) also had other
TMD diagnoses. No patient used any kind of centrally
acting medication prior to or during the study.
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There were no significant differences in mean (SD) P-
5-HT levels between the groups at baseline (GRA: 43.5
(66.3); CTR-group: 97.4 (131.4) nmol/L).
Finally, no differences in demographic data, pain inten-
sity, physical or emotional functioning and P-5-HT values
were found between patients who completed the study
and the drop-outs, and there were no differences in base-
line variables between responders and non-responders to
treatment.
Primary treatment outcome
The median weekly pain intensities are presented in
Table 3. The median weekly pain intensities had de-
creased significantly at all follow-ups in the GRA-group
(Friedman test; P < 0.05), but not in the CTR-group
(Friedman-test; P > 0.075).
At the 1-month follow-up 80 % of the patients in
GRA-group and 55 % in CTR-group reported a reduc-
tion of 30 % in weekly pain intensity (ITT-analysis). At
the 2-month follow-up these frequencies were 60 % in
the GRA-group and 30 % in the CTR-group, and at the
6-month follow-up 35 % and 10 %, respectively. All these
frequencies differed significantly between the groups
(Table 3).
Table 1 Demographic data of 40 patients with myofascial
temporomandibular disorders randomized to treatment with
active substance (GRA) or control substance (CTR)











Other European countries 2 3
Africa 1 0
Asia 2 1
South America 1 1
Marital status
Never married 8 6
Married 9 12
Divorced 3 2
Highest level of education
Elementary school 2 0
High school 9 10
College 9 10
GRA Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), CTR control
substance (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden).
There were no significant group differences
Table 2 Baseline pain variables, awareness of parafunctions and
diagnoses according to RDC/TMD Axis I in 40 patients with
myofascial temporomandibular disorders randomized to treatment
with active substance (GRA) or control substance (CTR)
GRA (n = 20) CTR (n = 20)
RDC/TMD Axis II
Duration of myofascial pain (months)
Mean (SD) 80 (54) 82 (66)
6-12 months 1 1
≥12 months 19 19
Frequency of myofascial pain
Recurrent 5 8
Persistent 15 12
Current myofascial pain intensity
(NRS 0–10)
Median (IQR) 6.0 (4.0) 6.0 (4.0)
Worst myofascial pain intensity last
6 months (NRS 0–10)
Median (IQR) 8.0 (2.0) 8.0 (2.0)
Average myofascial pain intensity last
6 months (NRS 0–10)
Median (IQR) 5.0 (3.0) 6.0 (5.0)
Pain area (AU)




Both day- and nighttime 15 15
RDC/TMD Axis I
Myofascial pain (Ia) 10 13
Myofascial pain (Ib) 10 7
Disc displacement with reduction (IIa)
One side 5 5
Both sides 7 7
Arthralgia (IIIa)
One side 1 0
Both sides 4 3
Osteoarthrosis (IIIc)
One side 0 1
Both sides 1 1
GRA Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), CTR control
substance (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden),
RDC/TMD Research Diagnostic Criteria for temporomandibular disorders,
SD Standard deviation, IQR Interquartile range (the 75th percentile minus the
25th percentile), NRS Numeric Rating Scale, AU Arbitrary units; There were no
significant differences between groups
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The frequencies for a reported reduction of 50 % in
weekly pain intensity were 40 % in both groups at the
1-month follow-up, 35 % in the GRA-group and 20 %
in the CTR-group at the 2-month follow-up, and at the
6-month follow-up 25 % in the GRA-group and 5 % in
the CTR-group. These frequencies differed significantly
between the groups at the 2- and 6-month follow-ups
(Table 3).
The numbers needed to treat (NNT) for a weekly pain
reduction of 30 % were 4 at the 1-month follow-up, 3.3
at the 2-month follow-up and 4 at the 6-month follow-up
in favor of granisetron (ITT-analysis). The NNT, for a
weekly pain reduction of 50 % were 6.7 at the 2-month
follow-up and 5 at the 6-month follow-up. The 1-month
NNTcould not be calculated because of an equal numbers
of responders in both groups.
The pain area had decreased significantly with approxi-
mately 40 % at the 1- and 2-months follow-ups, and with
55 % at the 6-month follow-up in the GRA-group. There




There were no significant differences between the groups
in physical functioning according to the GCPS and the
JDC, neither at baseline, nor at any of the follow-ups
(Table 3).
The MVO increased significantly after treatment in
the GRA-group (RM ANOVA; P < 0.001, but not in the
CTR-group (RM ANOVA; P = 0.051). There were no sig-
nificant differences between the groups at any time point
(Table 3). There were no significant changes in MVO
with pain within or between groups.
Emotional functioning
At baseline, most patients had moderate to severe scores
for depression and NSPhS without group differences.
Table 3 Pain and physical functioning before (baseline) and after (1-, 2- and 6-month follow-ups) repeated tender-point injections
with active substance (GRA) or control substance (CTR), in 40 patients with myofascial temporomandibular disorders
Baseline 1 month 2 months 6 months
GRA CTR GRA CTR GRA CTR GRA CTR
Pain variables n = 20 n = 20 n = 20 n = 18 n = 16 n = 8 n = 10 n = 5
Pain intensity 52 (29) 57 (24) 29 (41)a 29 (40) 32 (30)ab 36 (25) 24 (35)ab 34 (31)
Responders; ≥30 % - - 16c 11 12c 6 7c 2
Responders; ≥50 % - - 8 8 7d 4 5d 1
Pain area 100 100 62.4 (95.9)e 76.5 (99.9) 62.9 (105.6)e 74.8 (149.1) 44.5 (141.3)e 81.2 (189.3)
Physical functioning n = 19 n = 19 n = 20 n = 17 n = 16 n = 8 n = 10 n = 5
GCPS
Grade 0 5 12 8 11 7 6 6 2
Grade I 4 1 6 1 1 1 1 2
Grade II 9 4 4 2 3 1 1 1
Grade III 0 1 1 3 3 0 2 0
Grade IV 1 1 1 0 1 0 0 0
JDC
Score (0–12) 3 (5) 2 (4) 3 (5) 2 (4.5) 3 (4) 2 (5.5) 3 (5) 1 (3.5)
MVO
Without pain (mm) 41.1 (9.3) 44.0 (10.9) 42.9 (9.3) 47.6 (9.4) 43.3 (9.4)* 46.9 (9.4) 47.2 (10.8)* 46.1 (6.2)
With pain (mm) 49.7 (7.5) 52.8 (10.0) 47.9 (8.2) 52.8 (9.5) 49.2 (7.5) 51.3 (9.8) 49.3 (10.5) 50.4 (7.5)
The table presents median (IQR) weekly pain intensity (VAS; 0–100 mm), number of responders to treatment (≥30 % and ≥50 % decrease in pain intensity),
median (IQR) pain area (%) normalized to baseline, distribution of physical functioning assessed with the Graded Chronic Pain Scale (GCPS) and median (IQR)
limitation in jaw function assessed with the Jaw Disability Checklist (JDC) as well as the mean (SD) maximum voluntary mouth opening capacity (MVO) with and
without pain
GRA Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), CTR control substance (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden),
IQR Interquartile range (the 75th percentile minus the 25th percentile), SD Standard deviation, VAS Visual Analogue Scale, AU Arbitrary units
Physical functioning: GCPS: Grade 0 = no disability; Grade I = low disability and low intensity pain; Grade II = low disability and high intensity pain; Grade III = high
disability and moderately limiting; Grade IV = high disability and severely limiting
aSignificant decrease compared to baseline (Dunn’s test: 1 month: P = 0.031; 2 months: P = 0.008; 6 months: P = 0.007. bSignificant difference compared to the
CTR-group (Mann–Whitney U-test; 2-months: P = 0.009; 6-months: P = 0.031). cSignificant difference compared to the CTR-group (χ2-test; P < 0.001)
dSignificant difference compared to the CTR-group (χ2-test; 2 months: P = 0.027; 6 months: P < 0.001). eSignificant difference (Holm Sidak’s test; 1 month:
P = 0.039; 2 months: P = 0.039; 6 months: P = 0.042). *Significant difference compared to baseline (Holm Sidak’s test; P < 0.001), but not in the CTR-group
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None of the scores differed significantly between re-
sponders (30 %, 50 % reduction in pain intensity) and
non-responders to any treatment at baseline. The
depression-scores decreased significantly over time, in
both groups. The NSPhS-scores decreased significantly at
the 2-, and 6-month follow-ups in the GRA-group only
(Fig. 3).
Overall improvement
At the 1-month follow-up the majority of the patients in
both groups (GRA-group: 80 % and CTR-group: 78 %)
reported an overall improvement of “better”, “much better”
or “symptom-free” (ITT-analysis). At the 2-month follow
the corresponding frequencies were 81 % and 62 % re-
spectively, and at the 6-month follow-up 90 % in the
GRA-group and 60 % in the CTR-group. The differences
between groups were significant at the 2- and 6-month
follow-ups (Table 4).
Adverse events
Four patients in both groups reported mild, short lasting
adverse events, such as nausea, constipation, dizziness,
hematoma and itching after the first injection of sub-
stance. These adverse events did not occur after the sec-
ond and third injections. In the CTR-group one patient
reported hives to the first injection and ended the par-
ticipation, due to assumed allergic reaction.
Additional treatment outcomes
Changes in pressure pain threshold
The PPT over the masseter muscles and the reference
point did not differ between groups at baseline and there
were no significant differences between the right and left
masseter muscles at baseline. Further, PPT did not change
over time and there were no differences between sub-
stances at any time point (Fig. 4).
Correlations between outcome measures and P-5-HT
There were no significant correlations between P-5-HT
values and pain or emotional function at baseline. Neither
were there any significant correlations between treatment
effects regarding pain characteristics or depression- and
NSPhS-scores and P-5-HT values at baseline.
Discussion
To our knowledge this is the first RCT to show that
local treatment with a 5-HT3 blocker is effective for
chronic muscle pain. It was shown that, compared to
control, repeated intramuscular tender-point injections
with granisetron into jaw muscles of patients with M-
TMD had a clinically significant effect on pain intensity
and pain area. The effect was still evident 6 months after
treatment, when 35 % of the patients in the GRA-group
reported a 30 % improvement of pain intensity.
The pain relieving results from this study support previ-
ous results that intramuscular injections of 5-HT3-receptor
antagonists are effective for a number of muscular pain
conditions [23, 34]. Human experimental studies have
shown that granisetron reduces acute experimental muscle
pain intensity, pain area and allodynia induced by 5-HT,
hypertonic saline and acidic saline [14, 18, 39]. In patients
with fibromyalgia systemic administration of tropisetron
(5 mg), reduced pain intensity, tender-point count and im-
proved sleep [19, 20], indicating that 5-HT3-receptor antag-
onists might even be efficacious in more generalized pain
Fig. 2 Pain drawings at baseline and follow-ups after treatment with either granisetron or control substance. The pain area at baseline (a) and
follow-ups (1-month (b); 2-months, (c); 6-months (d)) after treatment with either granisetron (GRA-group) or control substance (isotonic saline;
CTR-group) in 40 patients with myofascial temporomandibular disorders. The darker the area is the larger is the overlap from the different
participants. The pain area decreased significantly in the GRA-group (Holm-Sidak’s test; P < 0.042) compared to baseline but not in the CTR-group
(Holm-Sidak’s test; P > 0.065)
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conditions, such as fibromyalgia. Although recent studies
suggest that peripheral nociceptive inputs, acting as “pain
generators”, play an important in maintaining the muscle
sensitization in patients with fibromyalgia, indicating that
local treatment of these “pain generators” to some extent
could decrease pain in patients with fibromyalgia [40], a
previous study with a local injection of granisetron into the
masseter muscle of patients with fibromyalgia did not show
any significant effect on pain or hyperalgesia [41]. However,
this study only used a single injection and not repeated
tender-point injections as the present and the pain reducing
effect was only assessed during 30 min. Thus, there is
a need to further investigate if repeated tender-point
injections of 5-HT3-receptor antagonists might have a
pain reducing effect in generalized pain conditions such as
fibromyalgia.
Fig. 3 Scores for depression and nonspecific physical symptoms at baseline and follow-ups after treatment. Median (IQR) differences in scores for
depression (a) and nonspecific physical symptoms (NSPhS) (b) in 40 patients with myofascial temporomandibular disorders before (baseline) and
after repeated intramuscular tender-point injections with granisetron (GRA-group) or control substance (isotonic saline; CTR-group). Depression-scores
are classified as normal (<0.535), moderate (0.535-1.105) and severe (>1.105), and the NSPhS-scores are classified as normal (<0.5), moderate (0.5-1) and
severe (>1). There were no significant differences between groups in depression- or in NSPhS-scores at baseline. *Significant difference compared to
baseline (Friedman-test with Dunn’s post-hoc test; P < 0.05)
Table 4 Overall improvement at 1 month, 2 as well as 6 months after repeated tender-point injections with active substance (GRA)
or control substance (CTR) in 40 patients with myofascial temporomandibular disorders
1 month 2 months 6 months
GRA (n = 20) CTR (n = 18) GRA (n = 16) CTR (n = 8) GRA (n = 10) CTR (n = 5)
Overall improvement
“No change” to “Worse” 4 4 3 3 1 2
“Better” to “Symptom-free” 16 14 13* 5 9* 3
“Better” 9 8 6 2 3 1
“Much better” or “Symptom-free” 7 9 7 3 6 2
GRA Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), CTR control substance (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden);
*Significant difference compared to the CTR-group (χ2-test; 2 months: P = 0.005, 6-months: P < 0.001)
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5-HT does not only evoke pain directly by 5-HT3-re-
ceptors, but also interacts with other substances in the
chemical milieu around nociceptors. Thus, blocking of
5-HT3-receptors may inhibit pain by different mecha-
nisms, which may explain the good analgesic effects. For
example, tropisetron is reported to inhibit 5-HT-induced
PGE2 release from macrophage-like synovial cells in vitro
[42] and to have an immunomodulatory function on cyto-
kines [43, 44]. Another reason for its good long-term effi-
cacy might be its route of metabolism by the liver, and
that it unlike the other 5-HT3-receptor antagonists has a
long half-life, and is not dependent on the isoenzyme cyto-
chrome P450 2D6 (CYP2D6), possibly leading to a good
efficacy also in ultrarapid metabolizers [31–33].
As many as 81 % (2-month follow-up) and 90 % (6-
month follow-up) of the patients in the GRA-group re-
ported an overall improvement of “better”, “much better”
or “symptom-free”, which was significantly higher than
the CTR-group with 62 % at the 2-month follow-up and
60 % at the 6-month follow-up, which is in line with previ-
ous intervention studies with other treatment modalities
in chronic M-TMD [45–49].
The NNT in the GRA-group was 3.3 at the 2-month
follow-up which is comparable to commonly used anal-
gesics for acute orofacial pain ranging from NNT 1.8
(naproxen, ibuprofen) to NNT 4.5 (aspirin) [50], or topical
NSAIDs for acute musculoskeletal conditions ranging from
NNT 1.8 (diclofenac) to far over NNT 4 (the majority of
topical NSAIDs) [51]. The NNT in the GRA-group was 4.0
at the long-term follow-up, which is better than salicylate-
containing topical analgesics for chronic musculoskeletal
pain (NNT 6.2) [52] It is also better than botulinum toxin
type A for treatment of M-TMD pain that showed
NNT values of 11 and 7, after 3 months and 6 months,
respectively [53]. Hence, taken together one can consider
intramuscularly administrated granisetron as an effective
treatment modality for M-TMD.
Previous studies in M-TMD patients have reported im-
proved physical functioning after treatment, shown as
lower GCPS severity and JDC-scores [45, 46]. This was
not found in this study, although seemingly there was a
change towards a lower severity grade in GCPS in the
GRA-group. The lack of statistical significance might be
due to low statistical power for the secondary outcomes
as power calculation was based on pain intensity.
However, there was a significant and clinically relevant
increase in mouth opening capacity at the 6-months
follow-up in the GRA-group indicating an improvement
in jaw functioning.
TMD-pain is associated with high levels of depression
and NSPhS, even higher than the other TMD diagnoses
[54], as was also found in this study. In both groups de-
pression- and NSPhS-scores decreased after treatment
and the scores remained decreased over time. This is
similar to results from cognitive-behavioral interventions
[55] and occlusal appliance therapy [46]. The finding that
also the CTR-group showed lower depression-scores is
probably due to the decreased pain-intensity.
In both groups serious adverse events were absent,
only a few patients reported mild and short-lasting ad-
verse events after the first injections of test substances.
Granisetron is considered efficacious and safe. However,
systemic administration of 5-HT3-blockers is commonly
associated with bothersome side effects such as consti-
pation, headache, and dizziness [9, 56]. Intramuscular
tender-point injections therefore offers a tempting alter-
native since no side effects have been reported after local
administration [14, 18, 26, 39, 41, 57, 58].
In contrast to several previous experimental studies
[17, 18, 41, 57] there was no effect on PPT in this study.
One explanation could be that the PPT was assessed the
first time one week after each treatment session, whereas
the previous studies assessed PPT during 30 min after
injection, indicating that any possible effect on PPT is
Fig. 4 Pressure pain thresholds at baseline and follow-ups after treatment with either granisetron or control substance. The mean (SEM) relative
changes (%) of pressure pain threshold (PPT) in 40 patients with myofascial temporomandibular disorders before (baseline) and after repeated
intramuscular tender-point injections with granisetron (GRA-group) or control substance (isotonic saline; CTR-group) over the a the right masseter
muscle b the left masseter muscle and c over a reference point on the tip of the right index finger. There was no change in PPT after treatment
with any of the substances
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short-lasting. Another reason might be related to sex. In
the previous studies increased PPT was mainly found in
men [10, 13, 17, 18, 59]. In this study the vast majority
of the participants were women, indicating that there
might be sex dependent differences.
Although there was a large difference between the
GRA-group and CTR-group in mean P-5-HT levels this
difference was not significant. Further, there were no
correlations between P-5-HT levels and any of the out-
come measures or differences between responders and
non-responders to treatment. This contrasts a previous
study using systemic ondansetron in 21 patients with
fibromyalgia, in which the serum 5-HT levels seem to be
lower at baseline in the responders [60].
The strengths with this study are the study design, i.e.
a prospective, controlled and double-blind RCT performed
in a well-characterized patient sample, that the outcome
measures recommended by IMMPACT [24, 25] to be used
in clinical pain trials were used, and that descriptive data is
reported. Hence, data may also be included in future meta-
analysis studies. However, even if the results are robust a
limited number of patients participated, why the study
should be replicated with a larger patient sample. It is also
an efficacy study, i.e. conducted in tertiary care. Therefore
future studies designed as effectiveness studies in general
practice are warranted. The generalizability of the findings
should also be investigated by studies in other chronic pain
disorders both local and generalized, such as work-related
trapezius myalgia or fibromyalgia. Further, there were tech-
nical problems with the blood samples. The first 14 (seven
from each treatment group) were missing and therefore the
results regarding P-5-HT levels must be considered cau-
tiously. Also, one could argue that a limitation of this study
is that no consideration was taken regarding the phase of
menstrual cycle or the use of contraceptives during the
treatment and follow-ups. However, the patients had four
consecutive visits one week apart, i.e. during all phases of
the menstrual cycle. Further, neither this nor our previous
studies have taken the menstrual cycle into consideration
since it has been shown that the intra-individual variability
in the pain response is greater than the influence of estro-
gen [61]. Finally, one can discuss the inclusion criteria
where chronic pain was defined as pain lasting for more
than 3 months and not 6 months which some consider as
normal healing phase. However, both 3 and 6 months pain
duration is used as time frame in the definition of chronic
pain [62, 63], and since no included patient had a duration
for less than 12 months this did not affect the outcome of
this study.
Conclusion
In conclusion, the results from the present study show
that granisetron has a clinically relevant pain reducing
effect, both in a short- and long-term aspect, in patients
with chronic M-TMD. Thus, repeated intramuscular
injections with granisetron may offer a novel and add-
itional treatment approach for patients with chronic
myalgia.
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